A Finckh1, S Dehler, K H Costenbader, C Gabay. 1. Division of Rheumatology, Department of Internal Medicine, University of Geneva, 26 Av. Beau-Sejour, 1211 Geneva 14, Switzerland. axel.finckh@hcuge.ch
Abstract
BACKGROUND: Smoking is a well-established environmental risk factor for the development of rheumatoid arthritis (RA). However, it remains unclear whether smoking influences RA disease progression and whether smokers have more radiographic damage progression than non-smokers over time. OBJECTIVE: To compare the rates of radiographic damage progression in current smokers and non-smokers in a large prospective RA cohort. METHODS: The SCQM-RA is a population-based registry monitoring disease activity, radiographic damage and symptoms at regular intervals. All patients in the SCQM-RA database with sequential plain radiographs were included. Joint erosions were assessed in 38 hand and foot joints with a validated scoring method. The rate of erosion progression was analysed using multivariate longitudinal regression models and adjusted for potential confounders. RESULTS: 2004 RA patients with a mean of 3.6 sequential radiographs and 3.1 years of follow-up were included. The 545 (27%) current smokers smoked on average 16 cigarettes per day and had a mean past smoking exposure of 20.6 pack-years. Radiographic joint damage progressed at a similar rate in current smokers and non-smokers (p = 0.26). However, smoking intensity was associated with a significant inverse dose-response; heavy smokers (>1 pack-day) progressed significantly less than non-smokers or moderate smokers (p<0.001). CONCLUSION: Radiographic joint damage progressed at an equivalent rate in smokers and non-smokers. Furthermore, a significant trend was observed for reduced radiographic progression and generally more favourable functional scores among heavy smokers, suggesting that cigarette smoke does not accelerate RA disease progression.
BACKGROUND: Smoking is a well-established environmental risk factor for the development of rheumatoid arthritis (RA). However, it remains unclear whether smoking influences RA disease progression and whether smokers have more radiographic damage progression than non-smokers over time. OBJECTIVE: To compare the rates of radiographic damage progression in current smokers and non-smokers in a large prospective RA cohort. METHODS: The SCQM-RA is a population-based registry monitoring disease activity, radiographic damage and symptoms at regular intervals. All patients in the SCQM-RA database with sequential plain radiographs were included. Joint erosions were assessed in 38 hand and foot joints with a validated scoring method. The rate of erosion progression was analysed using multivariate longitudinal regression models and adjusted for potential confounders. RESULTS: 2004 RA patients with a mean of 3.6 sequential radiographs and 3.1 years of follow-up were included. The 545 (27%) current smokers smoked on average 16 cigarettes per day and had a mean past smoking exposure of 20.6 pack-years. Radiographic joint damage progressed at a similar rate in current smokers and non-smokers (p = 0.26). However, smoking intensity was associated with a significant inverse dose-response; heavy smokers (>1 pack-day) progressed significantly less than non-smokers or moderate smokers (p<0.001). CONCLUSION: Radiographic joint damage progressed at an equivalent rate in smokers and non-smokers. Furthermore, a significant trend was observed for reduced radiographic progression and generally more favourable functional scores among heavy smokers, suggesting that cigarette smoke does not accelerate RA disease progression.
Authors: Wouter J de Jonge; Esmerij P van der Zanden; Frans O The; Maarten F Bijlsma; David J van Westerloo; Roelof J Bennink; Hans-Rudolf Berthoud; Satoshi Uematsu; Shizuo Akira; Rene M van den Wijngaard; Guy E Boeckxstaens Journal: Nat Immunol Date: 2005-07-17 Impact factor: 25.606
Authors: George A Wells; Maarten Boers; Beverley Shea; Peter M Brooks; Lee S Simon; C Vibeke Strand; Daniel Aletaha; Jennifer J Anderson; Claire Bombardier; Maxime Dougados; Paul Emery; David T Felson; Jaap Fransen; Dan E Furst; Johanna M W Hazes; Kent R Johnson; John R Kirwan; Robert B M Landewé; Marissa N D Lassere; Kaleb Michaud; Maria Suarez-Almazor; Alan J Silman; Josef S Smolen; Desiree M F M Van der Heijde; Piet L C M van Riel; Fred Wolfe; Peter S Tugwell Journal: J Rheumatol Date: 2005-10 Impact factor: 4.666
Authors: B Masdottir; T Jónsson; V Manfredsdottir ; A Víkingsson; A Brekkan; H Valdimarsson Journal: Rheumatology (Oxford) Date: 2000-11 Impact factor: 7.580
Authors: Rubina W Saeed; Santosh Varma; Tina Peng-Nemeroff; Barbara Sherry; David Balakhaneh; Jared Huston; Kevin J Tracey; Yousef Al-Abed; Christine N Metz Journal: J Exp Med Date: 2005-04-04 Impact factor: 14.307
Authors: Milena A Gianfrancesco; Laura Trupin; Stephen Shiboski; Mark van der Laan; Jonathan Graf; John Imboden; Jinoos Yazdany; Gabriela Schmajuk Journal: J Rheumatol Date: 2018-12-01 Impact factor: 4.666
Authors: Ahmad M Al-Bashaireh; Linda G Haddad; Michael Weaver; Debra Lynch Kelly; Xing Chengguo; Saunjoo Yoon Journal: J Environ Public Health Date: 2018-07-11
Authors: María Jezabel Haye Salinas; Soledad Retamozo; Ana Cecilia Alvarez; Hernán Maldonado Ficco; Fernando Dal Pra; Gustavo Citera; Mariana Benegas; Rafael Chaparro del Moral; Oscar Rillo; Anastasia Secco; Lucila Marino Claverie; Antonio Catalan Pellet; Josefina Marcos; Mercedes Argentina García; Juan Carlos Marcos; Ana Barbaglia; Verónica Bellomio; Alberto Berman; Cristian Quiroz; Enrique R Soriano; Federico Ceccato; Sergio Paira; Doralia Vazquez; Vicente Ricardo Juarez; Edson Javier Velozo; Gabriela Salvatierra; Francisco Caeiro Journal: Rheumatol Int Date: 2014-12-16 Impact factor: 2.631
Authors: Mario Andrés Quintana-Duque; Federico Rondon-Herrera; Enrique Calvo-Paramo; Juan Jose Yunis; Adriana Varela-Nariño; Antonio Iglesias-Gamarra Journal: Rheumatol Int Date: 2017-10-11 Impact factor: 2.631